IMPEDIMED LIMITED (IPD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IPD

IPD - IMPEDIMED LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.74
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.02

09 Feb
2026

0.000

OPEN

$0.02

0.000

HIGH

$0.02

54,121,941

LOW

$0.02

TARGET
$0.088 341.7% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RAP . RMD . SHG . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
IPD: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 1.2 - 0.9 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-1.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx12.7 M
Book Value Per Share xxxxxxxxxxxxxxx1.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-15.2 M
Net Profit Margin xxxxxxxxxxxxxxx-182.62 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-75.89 %
Return on Invested Capital xxxxxxxxxxxxxxx-60.93 %
Return on Assets xxxxxxxxxxxxxxx-52.43 %
Return on Equity xxxxxxxxxxxxxxx-75.89 %
Return on Total Capital xxxxxxxxxxxxxxx-62.98 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-15.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx14 M
Total Debt xxxxxxxxxxxxxxx14 M
Goodwill - Gross xxxxxxxxxxxxxxx3 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx22 M
Price To Book Value xxxxxxxxxxxxxxx3.46

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx1.0 M
Capex % of Sales xxxxxxxxxxxxxxx7.77 %
Cost of Goods Sold xxxxxxxxxxxxxxx28 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx9 M
Research & Development xxxxxxxxxxxxxxx0 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

30/01/2026

1

Speculative Buy

$0.045

125.00%

ImpediMed's December quarter (2Q26) revenue was up 8% q/q and 18% y/y, driven by 14% price increases on renewals, Bell Potter notes. Volumes rose q/q due to stronger RoW sales, offset by weak US unit volumes.

Cash flow improved materially with net operating outflow narrowing to -$2.9m (from -$6.0m), supported by an R&D tax incentive, leaving a solid cash balance of $18.5m.

The broker observes challenging US performance, with a slight decline in installed base and churn rising to 4%, reflecting hospital budget pressures.

Speculative Buy maintained. Target cut to 4.5c from 7c on -36% reduction in valuation due to lower volumes assumptions and rise in WACC by 50bps.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.20 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -0.50 cents.

Ord Minnett

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

05/02/2026

1

Speculative Buy

$0.06

200.00%

Canaccord Genuity maintains a Speculative Buy rating on ImpediMed and lowers its target to 6c from 7c.

While the breast cancer-related lymphedema (BCRL) business possesses a better reimbursement set-up than most medtechs ever get to enjoy, commentary highlights growth remains a struggle.

ImpediMed is yet to mount the sales acceleration Canaccord assessed was due. This pressure on the short-term revenue outlook naturally draws the broker's attention and focus to balance sheet risk.

Canaccord's valuation only considers the BCRL opportunity in the US, which the broker believes is appropriate given the business is constrained from investing much outside lymphoedema.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.00 cents.
Canaccord Genuity forecasts a full year FY27 dividend of 0.00 cents and EPS of minus -1.00 cents.
Access Extra Coverage Research History >

IPD STOCK CHART

FNArena News on IPD

1
Australian Broker Call *Extra* Edition – Feb 05, 2026

Feb 05 2026 - Daily Market Reports
2
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
3
Australian Broker Call *Extra* Edition – Oct 16, 2025

Oct 16 2025 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Oct 07, 2025

Oct 07 2025 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Sep 08, 2025

Sep 08 2025 - Daily Market Reports

Latest Medical Equipment & Devices News

1
GLP-1s Drive Strong Quarter For ResMed

Feb 02 2026 - Australia
2
ImpediMed Ready To Scale Up

Dec 16 2025 - Small Caps
3
Fisher & Paykel Healthcare’s Superior Profile

Dec 02 2025 - Australia
4
4DMedical Poised For A Recovery

Nov 25 2025 - Technicals
5
Treasure Chest: Pro Medicus

Nov 12 2025 - Treasure Chest
6
Tariff Uncertainty Negates ResMed’s Q1 Positives

Nov 05 2025 - Australia
7
Acquisition Loads Up Catapult

Oct 20 2025 - Small Caps
8
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
9
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
10
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia